Notice

UEG Week Virtual 2020 Celltrion Healthcare Industry Symposium 2020-09-16

Subcutaneous infliximab has been granted marketing authorisation in the EU, in adults regardless of body weight, in all previously approved indications for the IV formulation, including for the treatment of IBD in June 2020. During the United European Gastroenterology Week virtual 2020 held from October 11 to 13, a symposium is hosted by Celltrion Healthcare to review the latest clinical evidence for infliximab SC, explore bio-innovative approaches with biologic development, and discuss clinical practice of infliximab in the era of COVID-19.

공지사항 목록
등록일	제목	작성자
2020-04-13	Celltrion Group’s Statement on the development of a therapeutic antibody treatment to combat COVID-19	Celltrion Healthcare
2018-12-11	[Notice to shareholders] Celltrion Healthcare’s Statement on press release from YTN	Celltrion Healthcare
2018-11-19	Biosimilars have the potential to deliver dramatic cost savings for US and European healthcare systems	Celltrion Healthcare
2018-05-21	Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare	Celltrion Healthcare
2018-02-15	Celltrion’s Herzuma® (biosimilar trastuzumab) approved in Europe	Celltrion Healthcare
2016-12-27	Celltrion Healthcare website renewed	Celltrion Healthcare

CelltrionHealthcare